Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Floriani

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncologyVienna Ludovini, Lorenza Pistola, Vanesa Gregorc, et al.
Oncotarget|September 30, 2015
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyMirko Marabese, Monica Ganzinelli, Marina C Garassino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancerFrancesco Graziano, Annamaria Ruzzo, Fotios Loupakis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapyAnnamaria Ruzzo, Francesco Graziano, Fotios Loupakis, et al.
The Lancet. Oncology|July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialMarina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2009
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancerFotios Loupakis, Luca Pollina, Irene Stasi, et al.
European Radiology|December 18, 2008
Italian multicenter, prospective study to evaluate the negative predictive value of 16- and 64-slice MDCT imaging in patients scheduled for coronary angiography (NIMISCAD-Non Invasive Multicenter Italian Study for Coronary Artery Disease)Riccardo Marano, Francesco De Cobelli, Irene Floriani, et al.
The Oncologist|December 6, 2008
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practiceDaniele Santini, Fotios Loupakis, Bruno Vincenzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
Journal of the National Cancer Institute|April 21, 2005
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trialPierluigi Benedetti Panici, Angelo Maggioni, Neville Hacker, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncologyVienna Ludovini, Lorenza Pistola, Vanesa Gregorc, et al.
Oncotarget|September 30, 2015
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyMirko Marabese, Monica Ganzinelli, Marina C Garassino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancerFrancesco Graziano, Annamaria Ruzzo, Fotios Loupakis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapyAnnamaria Ruzzo, Francesco Graziano, Fotios Loupakis, et al.
The Lancet. Oncology|July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialMarina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2009
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancerFotios Loupakis, Luca Pollina, Irene Stasi, et al.
European Radiology|December 18, 2008
Italian multicenter, prospective study to evaluate the negative predictive value of 16- and 64-slice MDCT imaging in patients scheduled for coronary angiography (NIMISCAD-Non Invasive Multicenter Italian Study for Coronary Artery Disease)Riccardo Marano, Francesco De Cobelli, Irene Floriani, et al.
The Oncologist|December 6, 2008
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practiceDaniele Santini, Fotios Loupakis, Bruno Vincenzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
Journal of the National Cancer Institute|April 21, 2005
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trialPierluigi Benedetti Panici, Angelo Maggioni, Neville Hacker, et al.
Pageof 10